ABSTRACT
PURPOSE: To evaluate the effect of different doses of intravitreal triamcinolone acetonide on diffuse diabetic macular edema. METHODS: In a retrospective study, 44 eyes with diffuse diabetic macular edema were treated with an intravitreal injection of 4 mg (n=12 eyes), 8 mg (n=17) or 25 mg (n=15) of triamcinolone acetonide (TA). Optical coherence tomography, best-corrected logMAR visual acuity and Goldmann tonometry were performed at baseline, 1 week, and 1, 3, 6, 9 and 12 months after treatment. Mean follow-up was 9.8 months (standard deviation=2.3) with a range of 5-12 months. RESULTS: The duration of intravitreal TA effects on macular thickness and visual acuity increased with increasing dosage. An observed increase in intraocular pressure induced by TA was not significantly associated with dosage. CONCLUSIONS: In patients with diffuse diabetic macular edema who receive intravitreal TA, effects may last longer after a dosage of 25 mg, than after lower doses of 8 mg or 4 mg.
Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Diabetic Retinopathy/complications , Dose-Response Relationship, Drug , Follow-Up Studies , Glucocorticoids/administration & dosage , Injections , Intraocular Pressure , Macular Edema/diagnosis , Retrospective Studies , Time Factors , Tomography, Optical Coherence , Treatment Outcome , Triamcinolone Acetonide/administration & dosage , Visual Acuity , Vitreous BodyABSTRACT
PURPOSE: To report a case of epithelioid hemangioendothelioma of the lacrimal sac. METHODS: A 51-year-old woman was admitted to our hospital because of tearing on the left eye. Nasolacrimal duct stenosis was found on dacryocystogram. After observation of 2 months, the tearing became worse and a palpable mass at the medial canthal area was noted. Orbital computed tomography showed the tumor of the left lacrimal sac and complete excision of the tumor and sac was performed. RESULTS: Pathologic diagnosis of the excised mass was epithelioid-hemagioendothelioma. There was no evidence of recurrence until last follow-up at postoperative 4 months.